Two big health systems will not administer a newly approved drug to patients to treat Alzheimer disease; drug overdose deaths hit a new high in 2020 Johnson & Johnson (J&J) recall sunscreen products after detecting a cancer-causing chemical.
In light of the controversy surrounding the FDA approval of Biogen’s Alzheimer drug, Aduhelm (aducanumab), 2 major health systems, Cleveland Clinic and Mount Sinai, have announced they will not be administering the drug to patients. According to The New York Times, the decision was driven by institutions calling for a federal investigation of the FDA's decision and the agency’s relationship with Biogen. Experts also expressed concerns regarding safety and efficacy data, saying that it is unclear whether the drug works to slow cognitive decline or provide a significant benefit to patients. Additionally, the price of the drug is exorbitant, at $56,000 a year. A recent survey of nearly 200 neurologists and primary care physicians found that a majority disagreed with the FDA’s decision and did not plan to prescribe Aduhelm to patients.
According to The Wall Street Journal, drug overdose deaths in the United States skyrocketed nearly 30% in 2020, a direct impact of the COVID-19 pandemic. The estimated 93,331 deaths accounted for a record high and represents the sharpest annual increase in more than 30 years. In 2019, 72,151 deaths were attributed to overdoses. The pandemic intensified the overdose epidemic by forcing individuals to self-isolate, causing trauma and contributing to job losses. The surge was largely driven by an increase in fentanyl use across the country. Overdose deaths started to climb in fall 2019 with the spread of fentanyl but rose more steeply in March 2020, when pandemic-related shutdowns and social-distancing measures became more prevalent in the United States. In addition, to fentanyl-related deaths, deaths from methamphetamine and cocaine overdoses rose.
Johnson & Johnson (J&J) has announced a voluntary recall for 5 Neutrogena and Aveeno brand aerosol sunscreen products after low levels of benzene, a known carcinogen, benzene, were detected in some samples. Reuters reported that the company has instructed consumers to stop using and discard the products and for distributors and retailers to stop selling them “out of an abundance of caution.” J&J said that benzene is not an ingredient in its sunscreen and that it is investigating how the products became contaminated, while also emphasizing that the levels detected would likely not cause adverse health consequences. The recall represents another issue for J&J, which already is facing billions of dollars in settlement costs resulting from lawsuits over its talcum-based baby powder, vaginal mesh implants, and opioid painkillers. The company is also facing production challenges related to its COVID-19 vaccine, which is being investigated for having a potential link to Guillain-Barré Syndrome.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More